Considering the limited therapeutic options for SCLC, it is important to identify markers of response and toxicity and to characterize DLL3 as a dynamic biomarker, in addition to the refinement of adverse event (AE) management approaches. The gene discussed is DLL3; the disease is small cell lung carcinoma.